Sichuan Kelun-Biotech Unveils Positive Results from Multiple Innovative Drug Studies at 2025 ESMO Congress

Reuters

10/20

<a href="https://laohu8.com/S/002422">Sichuan Kelun</a>-Biotech Unveils Positive Results from Multiple Innovative Drug Studies at 2025 ESMO Congress

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the presentation of results from multiple clinical studies at the 2025 European Society for Medical Oncology (ESMO) Congress, held in Berlin, Germany from October 17 to 21, 2025. The studies included data on sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate $(ADC)$, trastuzumab botidotin (A166), a HER2-directed ADC, and SKB315, a Claudin18.2 ADC. Two studies of sac-TMT were selected for Late Breaking Abstract oral presentation, including a Phase 3 study in EGFR-mutated non-small cell lung cancer following progression on EGFR-tyrosine kinase inhibitors. The company also reported ongoing research on SKB315 in combination with immunotherapy and as monotherapy in tumors expressing Claudin18.2. The company cautioned that these drugs are not yet approved for all indications and may not ultimately be successfully developed or commercialized.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2576004457"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576004457\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576004457?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 07:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576004457","market":"fut","top_or_hot":-1,"title":"Sichuan Kelun-Biotech Unveils Positive Results from Multiple Innovative Drug Studies at 2025 ESMO Congress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/002422\">Sichuan Kelun</a>-Biotech Unveils Positive Results from Multiple Innovative Drug Studies at 2025 ESMO Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the presentation of results from multiple clinical studies at the 2025 European Society for Medical Oncology (ESMO) Congress, held in Berlin, Germany from October 17 to 21, 2025. The studies included data on sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, trastuzumab botidotin (A166), a HER2-directed ADC, and SKB315, a Claudin18.2 ADC. Two studies of sac-TMT were selected for Late Breaking Abstract oral presentation, including a Phase 3 study in EGFR-mutated non-small cell lung cancer following progression on EGFR-tyrosine kinase inhibitors. The company also reported ongoing research on SKB315 in combination with immunotherapy and as monotherapy in tumors expressing Claudin18.2. The company cautioned that these drugs are not yet approved for all indications and may not ultimately be successfully developed or commercialized.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sichuan Kelun-Biotech Unveils Positive Results from Multiple Innovative Drug Studies at 2025 ESMO Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSichuan Kelun-Biotech Unveils Positive Results from Multiple Innovative Drug Studies at 2025 ESMO Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-20 07:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/002422\">Sichuan Kelun</a>-Biotech Unveils Positive Results from Multiple Innovative Drug Studies at 2025 ESMO Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the presentation of results from multiple clinical studies at the 2025 European Society for Medical Oncology (ESMO) Congress, held in Berlin, Germany from October 17 to 21, 2025. The studies included data on sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, trastuzumab botidotin (A166), a HER2-directed ADC, and SKB315, a Claudin18.2 ADC. Two studies of sac-TMT were selected for Late Breaking Abstract oral presentation, including a Phase 3 study in EGFR-mutated non-small cell lung cancer following progression on EGFR-tyrosine kinase inhibitors. The company also reported ongoing research on SKB315 in combination with immunotherapy and as monotherapy in tumors expressing Claudin18.2. The company cautioned that these drugs are not yet approved for all indications and may not ultimately be successfully developed or commercialized.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002422","symbol_name":"科伦药业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251019:nNDL7FfVX3:1","article_id":"2576004457","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576004457","pubTimestamp":1760916746,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the presentation of results from multiple clinical studies at the 2025 European Society for Medical Oncology  Congress, held in Berlin, Germany from October 17 to 21, 2025. The studies included data on sacituzumab tirumotecan , a TROP2-directed antibody-drug conjugate , trastuzumab botidotin , a HER2-directed ADC, and SKB315, a Claudin18.2 ADC. Two studies of sac-TMT were selected for Late Breaking Abstract oral presentation, including a Phase 3 study in EGFR-mutated non-small cell lung cancer following progression on EGFR-tyrosine kinase inhibitors. The company also reported ongoing research on SKB315 in combination with immunotherapy and as monotherapy in tumors expressing Claudin18.2. The company cautioned that these drugs are not yet approved for all indications and may not ultimately be successfully developed or commercialized.Disclaimer: This news brief was created by Public Technologies  using generative artificial inte","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"002422":"科伦药业","BK1161":"生物科技","06990":"科伦博泰生物-B","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0060":"抗癌","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","BK0239":"医药制造"},"translate_title":"四川科伦生物在2025年ESMO大会上公布多项创新药物研究积极成果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002422":0.9,"06990":0.9},"content_text":"Sichuan Kelun-Biotech Unveils Positive Results from Multiple Innovative Drug Studies at 2025 ESMO Congress\n    \n\n        Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the presentation of results from multiple clinical studies at the 2025 European Society for Medical Oncology (ESMO) Congress, held in Berlin, Germany from October 17 to 21, 2025. The studies included data on sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate $(ADC)$, trastuzumab botidotin (A166), a HER2-directed ADC, and SKB315, a Claudin18.2 ADC. Two studies of sac-TMT were selected for Late Breaking Abstract oral presentation, including a Phase 3 study in EGFR-mutated non-small cell lung cancer following progression on EGFR-tyrosine kinase inhibitors. The company also reported ongoing research on SKB315 in combination with immunotherapy and as monotherapy in tumors expressing Claudin18.2. The company cautioned that these drugs are not yet approved for all indications and may not ultimately be successfully developed or commercialized.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}